カテゴリ： GlobalData, アメリカ, 企業調査

Danaher Corporation (DHR)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Danaher Corporation (DHR) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011722
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月13日
◆ページ数：140
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Danaher Corporation (Danaher) is a medical technology company which designs, manufactures and markets medical, professional, commercial and industrial products and services. The company offers a wide range of testing instruments, communications solutions, water quality systems, medical diagnostics solutions, life science research tools, professional microscopes, dental products, product identification solutions, automation solutions and sensors and controls solutions. Danaher offers its products and services in four major areas namely, life sciences; diagnostics; dental; and environmental and applied solutions. The company operates manufacturing, sales, distribution, service and administrative facilities in Europe, Australia, Asia and the Americas. The company distributes its products to its customers across the Americas; Europe, Middle East, Africa and Asia-Pacific through direct sales personnel and independent distributors. Danaher is headquartered in Washington DC, the US.

Danaher Corporation (DHR) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Danaher Corporation, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Danaher Corporation, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Danaher Corporation, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Danaher Corporation, Medical Equipment, Deals By Market, 2011 to YTD 2017 11
Danaher Corporation, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Danaher Corporation, Medical Equipment, Deal Details 16
Asset Purchase 16
Beckman Coulter Acquires Clinical Microbiology Business from Siemens Healthcare Diagnostics 16
AB Sciex Acquires Mass Spectrometry Business From Labindia Instruments 17
Leica Microsystems Acquires Microscopy And Histopathology Divisions From Labindia 18
Beckman Coulter Acquires Clinical Products Distribution Business From Dong-A Pharma, For US$10 Million 19
Partnerships 20
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics 20
Smart Imaging Enters Into Licensing Agreement With Leica Microsystems 21
Prosolia Enters Into Licensing Agreement With AB Sciex For ORNL Analytical Technology 22
Leica Microsystems Enters Into Licensing Agreement With Max Planck Society And German Cancer Research 23
Olympus America Enters Into Licensing Agreement With Leica Microsystems 24
Grifols and Beckman Coulter Enter into Distribution Agreement 25
SpeeDx Enters into Distribution Agreement with Cepheid 26
Novacyt Enters into Partnership with Cepheid 27
DiaSorin Enters into Agreement with Beckman Coulter 28
AB Sciex Enters into Co-Marketing Agreement with Pressure BioSciences 29
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics 30
Vomaris Innovations Enters into Distribution Agreement with Metrex Research 31
DiaSorin Enters into Distribution Agreement with Beckman Coulter Diagnostics 32
NanoCellect Biomedical Enters into Co-Development Agreement with Invetech 33
Bio-Rad Labs Extends Agreement with Beckman Coulter Diagnostics 34
NeoStem Enters into Co-Development Agreement with Invetech 35
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers 36
Ab Sciex Enters into Co-Development Agreement with Dalton Pharma 37
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 38
Invetech Enters Into Co-Development Agreement With Biocartis For Evalution 39
Ab Sciex, Genedata And Leco Enter Into Agreement For Metabolomics Data Analysis Solution 40
Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 41
CellaVision Expands Distribution Agreement With Beckman Coulter 42
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University 43
IRIS International Enters Into Distribution Agreement With Alifax 44
Leica Microsystems Enters Into Integration Agreement With Indica Labs 45
Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 46
Radisens Diagnostics Enters Into Co-Development Agreement With Beckman Coulter For HDR Detection Technology 47
Hamilton Thorne Expands Co-Marketing Agreement With Leica Microsystems 48
Iris International Enters Into Distribution Agreement With Fisher HealthCare 49
Leica Microsystems Enters Into Co-Marketing Agreement With TrueVision Systems 50
China Medical Technologies Enters Into Co-Development Agreement With Leica Microsystems 51
Atonomics Enters Into An Agreement With Beckman Coulter 52
Leica Microsystems Enters Into Co-Marketing Agreement With Definiens 53
IRIS International Enters Into Co-Development Agreement With Fujirebio 54
AB Sciex Enters Into Co-Development Agreement With ARUP Labs 55
Cepheid Enters Into Co-Development Agreement With FIND 56
Transgene Signs Agreement With Beckman Coulter 57
Equity Offering 58
Danaher Completes Public Offering Of Common Stock For US$996.18 Million 58
Debt Offering 60
Danaher Raises USD671.6 Million in Public Offering of 1.2% Notes Due 2027 60
Danaher Raises USD279.8 Million in Public Offering of Floating Rate Notes Due 2022 62
Danaher Raises USD500 Million in Public Offering of 1.65% Notes Due 2018 64
Danaher Raises USD500 Million in Public Offering of 3.35% Notes Due 2025 66
Danaher Raises USD500 Million in Public Offering of 2.4% Notes Due 2020 68
Danaher Raises USD500 Million in Public Offering of 4.375% Notes Due 2045 70
Danaher Raises USD500 Million in Public Offering of Notes Due 2017 72
Danaher Raises USD671 Million in Public Offering of 1% Notes Due 2019 74
Danaher Raises USD894.5 Million in Public Offering of 2.5% Notes Due 2025 76
Danaher Raises USD894.5 Million in Public Offering of 1.7% Notes Due 2022 78
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million 80
Nobel Biocare Announces Public Offering Of Bonds For US$136 Million 82
Danaher Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$300 Million 83
Danaher Completes Public Offering Of 2.3% Senior Notes Due 2016 For US$500 Million 85
Danaher Completes Public Offering Of 3.9% Senior Notes Due 2021 For US$600 Million 87
Danaher Completes Public Offering Of 1.3% Senior Notes Due 2014 For US$400 Million 89
Asset Transactions 91
GENEWIZ to Acquire Genomic Services Business of Beckman Coulter 91
Haemonetics Completes Acquisition Of Blood Collection, Filtration And Processing Product Lines From Pall For US$551 Million 92
Leica Microsystems Acquires Microscopy And Histopathology Divisions From Labindia 94
AB Sciex Acquires Mass Spectrometry Business From Labindia Instruments 95
Acquisition 96
Danaher Acquires Cepheid 96
Danaher to Acquire Phenomenex 98
Danaher Acquires Pall for USD13.8 Billion 99
Leica Microsystems to Acquire Bioptigen 101
Danaher Acquires 97% Stake in Nobel Biocare for USD2.17 Billion in Tender Offer 102
Fluke Biomedical Acquires Unfors RaySafe, Diagnostic Imaging Devices Manufacture 104
Leica Microsystems And Leica Biosystems Acquire Aotec Instrumentos 105
Quest Diagnostics Completes Sale Of HemoCue To Radiometer Medical For US$300 Million 106
Danaher Completes Acquisition Of 91.6% Stake In Iris International, Diagnostic Test Maker, For US$324 Million 108
Leica Biosystems Completes Acquisition Of Aperio Technologies 110
Beckman Coulter Acquires Blue Ocean Biomedical From Npe Systems 112
Pall Corporation Completes Acquisition Of ForteBio For US$142.5 Million 113
Tektronix Acquires Optametra 115
Danaher Completes Acquisition Of Beckman Coulter 116
Danaher Corporation – Key Competitors 118
Danaher Corporation – Key Employees 119
Danaher Corporation – Locations And Subsidiaries 120
Head Office 120
Other Locations & Subsidiaries 120
Business Unit 126
Recent Developments 127
Strategy And Business Planning 127
May 04, 2016: Danaher Announces Anticipated Fortive Separation Date 127
Financial Announcements 128
Oct 19, 2017: Danaher Reports Third Quarter 2017 Results 128
Jul 20, 2017: Danaher Reports Second Quarter 2017 Results 129
Apr 20, 2017: Danaher Reports First Quarter 2017 Results 130
Jan 31, 2017: Danaher Reports Fourth Quarter And Full Year 2016 Results 131
Oct 20, 2016: Danaher Reports Third Quarter 2016 Results 132
Jul 25, 2016: Danaher Reports Second Quarter 2016 Results 133
Apr 21, 2016: Danaher Reports Record First Quarter 2016 Results 134
Jan 26, 2016: Danaher Reports Record Fourth Quarter And Full Year 2015 Results 135
Corporate Communications 136
Nov 28, 2017: Danaher Announced its Leadership Appointment 136
Feb 21, 2017: Danaher Announces Appointment Of Raymond C. Stevens, Ph.D. To Danaher Board 137
Dec 01, 2016: Danaher announces leadership appointment 138
Jul 14, 2016: Danaher Announces Appointment Of Robert J. Hugin To Danaher Board 139
Appendix 140
Methodology 140
About GlobalData 140
Contact Us 140
Disclaimer 140

List of Tables
Danaher Corporation, Medical Equipment, Key Facts, 2016 2
Danaher Corporation, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Danaher Corporation, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Danaher Corporation, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Danaher Corporation, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Danaher Corporation, Deals By Market, 2011 to YTD 2017 11
Danaher Corporation, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Beckman Coulter Acquires Clinical Microbiology Business from Siemens Healthcare Diagnostics 16
AB Sciex Acquires Mass Spectrometry Business From Labindia Instruments 17
Leica Microsystems Acquires Microscopy And Histopathology Divisions From Labindia 18
Beckman Coulter Acquires Clinical Products Distribution Business From Dong-A Pharma, For US$10 Million 19
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics 20
Smart Imaging Enters Into Licensing Agreement With Leica Microsystems 21
Prosolia Enters Into Licensing Agreement With AB Sciex For ORNL Analytical Technology 22
Leica Microsystems Enters Into Licensing Agreement With Max Planck Society And German Cancer Research 23
Olympus America Enters Into Licensing Agreement With Leica Microsystems 24
Grifols and Beckman Coulter Enter into Distribution Agreement 25
SpeeDx Enters into Distribution Agreement with Cepheid 26
Novacyt Enters into Partnership with Cepheid 27
DiaSorin Enters into Agreement with Beckman Coulter 28
AB Sciex Enters into Co-Marketing Agreement with Pressure BioSciences 29
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics 30
Vomaris Innovations Enters into Distribution Agreement with Metrex Research 31
DiaSorin Enters into Distribution Agreement with Beckman Coulter Diagnostics 32
NanoCellect Biomedical Enters into Co-Development Agreement with Invetech 33
Bio-Rad Labs Extends Agreement with Beckman Coulter Diagnostics 34
NeoStem Enters into Co-Development Agreement with Invetech 35
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers 36
Ab Sciex Enters into Co-Development Agreement with Dalton Pharma 37
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 38
Invetech Enters Into Co-Development Agreement With Biocartis For Evalution 39
Ab Sciex, Genedata And Leco Enter Into Agreement For Metabolomics Data Analysis Solution 40
Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 41
CellaVision Expands Distribution Agreement With Beckman Coulter 42
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University 43
IRIS International Enters Into Distribution Agreement With Alifax 44
Leica Microsystems Enters Into Integration Agreement With Indica Labs 45
Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 46
Radisens Diagnostics Enters Into Co-Development Agreement With Beckman Coulter For HDR Detection Technology 47
Hamilton Thorne Expands Co-Marketing Agreement With Leica Microsystems 48
Iris International Enters Into Distribution Agreement With Fisher HealthCare 49
Leica Microsystems Enters Into Co-Marketing Agreement With TrueVision Systems 50
China Medical Technologies Enters Into Co-Development Agreement With Leica Microsystems 51
Atonomics Enters Into An Agreement With Beckman Coulter 52
Leica Microsystems Enters Into Co-Marketing Agreement With Definiens 53
IRIS International Enters Into Co-Development Agreement With Fujirebio 54
AB Sciex Enters Into Co-Development Agreement With ARUP Labs 55
Cepheid Enters Into Co-Development Agreement With FIND 56
Transgene Signs Agreement With Beckman Coulter 57
Danaher Completes Public Offering Of Common Stock For US$996.18 Million 58
Danaher Raises USD671.6 Million in Public Offering of 1.2% Notes Due 2027 60
Danaher Raises USD279.8 Million in Public Offering of Floating Rate Notes Due 2022 62
Danaher Raises USD500 Million in Public Offering of 1.65% Notes Due 2018 64
Danaher Raises USD500 Million in Public Offering of 3.35% Notes Due 2025 66
Danaher Raises USD500 Million in Public Offering of 2.4% Notes Due 2020 68
Danaher Raises USD500 Million in Public Offering of 4.375% Notes Due 2045 70
Danaher Raises USD500 Million in Public Offering of Notes Due 2017 72
Danaher Raises USD671 Million in Public Offering of 1% Notes Due 2019 74
Danaher Raises USD894.5 Million in Public Offering of 2.5% Notes Due 2025 76
Danaher Raises USD894.5 Million in Public Offering of 1.7% Notes Due 2022 78
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million 80
Nobel Biocare Announces Public Offering Of Bonds For US$136 Million 82
Danaher Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$300 Million 83
Danaher Completes Public Offering Of 2.3% Senior Notes Due 2016 For US$500 Million 85
Danaher Completes Public Offering Of 3.9% Senior Notes Due 2021 For US$600 Million 87
Danaher Completes Public Offering Of 1.3% Senior Notes Due 2014 For US$400 Million 89
GENEWIZ to Acquire Genomic Services Business of Beckman Coulter 91
Haemonetics Completes Acquisition Of Blood Collection, Filtration And Processing Product Lines From Pall For US$551 Million 92
Leica Microsystems Acquires Microscopy And Histopathology Divisions From Labindia 94
AB Sciex Acquires Mass Spectrometry Business From Labindia Instruments 95
Danaher Acquires Cepheid 96
Danaher to Acquire Phenomenex 98
Danaher Acquires Pall for USD13.8 Billion 99
Leica Microsystems to Acquire Bioptigen 101
Danaher Acquires 97% Stake in Nobel Biocare for USD2.17 Billion in Tender Offer 102
Fluke Biomedical Acquires Unfors RaySafe, Diagnostic Imaging Devices Manufacture 104
Leica Microsystems And Leica Biosystems Acquire Aotec Instrumentos 105
Quest Diagnostics Completes Sale Of HemoCue To Radiometer Medical For US$300 Million 106
Danaher Completes Acquisition Of 91.6% Stake In Iris International, Diagnostic Test Maker, For US$324 Million 108
Leica Biosystems Completes Acquisition Of Aperio Technologies 110
Beckman Coulter Acquires Blue Ocean Biomedical From Npe Systems 112
Pall Corporation Completes Acquisition Of ForteBio For US$142.5 Million 113
Tektronix Acquires Optametra 115
Danaher Completes Acquisition Of Beckman Coulter 116
Danaher Corporation, Key Competitors 118
Danaher Corporation, Key Employees 119
Danaher Corporation, Other Locations 120
Danaher Corporation, Subsidiaries 120
Danaher Corporation, Business Unit 126

★海外企業調査レポート[Danaher Corporation (DHR)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • HL Global Enterprises Limited：戦略・SWOT・企業財務分析
    HL Global Enterprises Limited - Strategy, SWOT and Corporate Finance Report Summary HL Global Enterprises Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Berkshire Hathaway Energy：企業の戦略・SWOT・財務分析
    Berkshire Hathaway Energy - Strategy, SWOT and Corporate Finance Report Summary Berkshire Hathaway Energy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Varian Medical Systems Inc (VAR)：企業の財務・戦略的SWOT分析
    Varian Medical Systems Inc (VAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Zhejiang Hisun Pharmaceutical Co Ltd (600267)：製薬・医療：M&Aディール及び事業提携情報
    Summary Zhejiang Hisun Pharmaceutical Co Ltd (Hisun) is a pharmaceutical company that manufactures and commercializes active pharmaceutical ingredients, antibiotics and anticancer drugs. The company offers active pharmaceutical ingredients and bulk drugs used in anti-neoplastics. It offers products …
  • QEP Resources Inc (QEP)：石油・ガス：M&Aディール及び事業提携情報
    Summary QEP Resources Inc (QEP) is an independent oil and natural gas exploration and production company. It has operating interests in Northern Region chiefly in North Dakota, Wyoming and Utah; and Southern Region essentially in Texas and Louisiana. In Northern Region, the company owns productive w …
  • Global Partners LP (GLP)-石油・ガス分野：企業M&A・提携分析
    Summary Global Partners LP (Global Partners) is a midstream logistics and marketing company. It carries out purchasing, selling and logistics of transporting domestic and Canadian crude oil and other products by rail across its virtual pipeline from the mid-continent region of the US and Canada to t …
  • BRS Aerospace：企業の戦略・SWOT・財務情報
    BRS Aerospace - Strategy, SWOT and Corporate Finance Report Summary BRS Aerospace - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • John Wood Group Plc (WG.)：企業の財務・戦略的SWOT分析
    John Wood Group Plc (WG.) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • BOOM Logistics Ltd (BOL)：企業の財務・戦略的SWOT分析
    BOOM Logistics Ltd (BOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Catalyst Biosciences Inc (CBIO)：企業の財務・戦略的SWOT分析
    Summary Catalyst Biosciences Inc (Catalyst Biosciences), formerly Targacept Inc, is a clinical-stage biopharmaceutical company that develops protease-based advanced medicines to treat hematological indications. The company specializes in hemostasis, with focus on subcutaneous prophylaxis of hemophil …
  • Pierrel Spa (PRL)：製薬・医療：M&Aディール及び事業提携情報
    Summary Pierrel Spa (Pierrel) is a pharmaceutical company that offers contract services to biopharmaceutical and life sciences industries across the world. The company offers services in the areas of contract research, discovery of medicinal product candidates, clinical research and contract manufac …
  • Endress+Hauser AG：企業の戦略的SWOT分析
    Endress+Hauser AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Baron Oil Plc (BOIL)：石油・ガス：M&Aディール及び事業提携情報
    Summary Baron Oil Plc (Baron Oil), formerly Gold Oil PLC is an oil and gas exploration and production company. The company identifies and develops crude oil and natural gas interests in Latin America including Peru and Colombia. It holds working interests of Nancy Burdine Maxine oil field, oil and g …
  • Microsoft Corporation (MSFT)-医療機器分野：企業M&A・提携分析
    Summary Microsoft Corporation (Microsoft) is a technology-based company that develops, licenses, and supports software products, services, and devices. The company offers a comprehensive range of operating systems, cross-device productivity applications, server applications, business solution applic …
  • Adimmune Corp (4142)：製薬・医療：M&Aディール及び事業提携情報
    Summary Adimmune Corp (Adimmune) is a biopharmaceutical company that manufactures diagnostics, vaccines, and biological products for various diseases. The corporation’s products include tetanus toxoid adsorbed vaccine, influenza vaccine, Japan encephalitis vaccine, and ah1n1 vaccine. It also provide …
  • Trustpower Limited (TPW)-エネルギー分野：企業M&A・提携分析
    Summary TrustPower Limited (Trustpower) is an energy utility that retails electricity, gas and telecommunication services. The company produces electricity from wind, hydro, and diesel sources. It owns and operates various power projects across New Zealand and Australia. Trustpower also leases elect …
  • Keio Corporation (9008)：企業の財務・戦略的SWOT分析
    Keio Corporation (9008) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Gymboree Group, Inc.：企業の戦略的SWOT分析
    Gymboree Group, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Covis Pharma Sarl：製薬・医療：M&Aディール及び事業提携情報
    Summary Covis Pharma Sarl (Covis Pharma), a subsidiary of Concordia International Corp is a specialty pharmaceutical company that develops and markets drugs for the treatment of life-threatening conditions and chronic illnesses. The company develops products for central nervous system and rheumatic …
  • HTC Corporation：戦略・SWOT・企業財務分析
    HTC Corporation - Strategy, SWOT and Corporate Finance Report Summary HTC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆